Ophthalmologic Center of the Second Hospital, Jilin University, Ziqiang Street 218, Changchun, 130000, People's Republic of China.
Int Ophthalmol. 2022 Jul;42(7):2063-2069. doi: 10.1007/s10792-021-02204-2. Epub 2022 Jan 4.
To evaluate the effectiveness and safety of the dexamethasone intravitreal implant (DEX-I) in Non-Infectious Uveitis (NIU) in Chinese patients.
Ninety-one eyes of 77 patients (56 men, 21 women) receiving 130 implant injections for NIU were included. Treatment indication, uveitis diagnosis, best-corrected visual acuity (BCVA), central retinal thickness (CRT), vitreous haze score, intraocular pressure, phakic status, number of injections, time to reinjection, and systemic treatments were collected at baseline, 1 week, 1 month, 3 and 6 months after treatment.
All patients were followed for at least 12 weeks and had a mean follow-up period of 5.1 months (range, 3-14 months) after the first implant. The main treatment indications were macular edema (ME), retinal vasculitis, retinal vasculitis with ME. Sixty-one eyes (67.03%) received only one injection, while 31 eyes (32.97%) received two or more. In eyes that received 2 injections, the mean time to the second injection was 3.83 months and in those that received 3 injections, the mean time to the third injection was 7.5 months. BCVA and CRT significantly improved at 1 week, 1 month, 3 months, and 6 months after treatment. When compared to baseline, the mean prednisone (or equivalent) dosage significantly decreased at 3- and 6-month follow-up evaluations after DEX implantation.14.29% of eyes developed a transient increase in intraocular pressure, and a cataract was removed from 1 phakic eye.
DEX implants, either alone or in combination with common adjunctive NIU treatments, is safe and effective in the treatment of NIU in Chinese patients.
评估地塞米松玻璃体内植入剂（DEX-I）在治疗中国患者非感染性葡萄膜炎（NIU）中的有效性和安全性。
纳入了 77 例（56 名男性，21 名女性）91 只眼因 NIU 接受 130 次植入治疗的患者。收集了治疗适应证、葡萄膜炎诊断、最佳矫正视力（BCVA）、中心视网膜厚度（CRT）、玻璃体混浊评分、眼内压、晶状体状态、注射次数、再次注射时间和全身治疗等数据，分别在基线、治疗后 1 周、1 个月、3 个月和 6 个月进行评估。
所有患者均随访至少 12 周，首次植入后平均随访时间为 5.1 个月（范围 3-14 个月）。主要治疗适应证为黄斑水肿（ME）、视网膜血管炎、伴 ME 的视网膜血管炎。61 只眼（67.03%）仅接受了 1 次注射，而 31 只眼（32.97%）接受了 2 次或更多次注射。接受 2 次注射的眼，第 2 次注射的平均时间为 3.83 个月，接受 3 次注射的眼，第 3 次注射的平均时间为 7.5 个月。治疗后 1 周、1 个月、3 个月和 6 个月，BCVA 和 CRT 显著改善。与基线相比，DEX 植入后 3 个月和 6 个月随访时，泼尼松（或等效物）剂量显著降低。14.29%的眼一过性眼压升高，1 例晶状体混浊眼行白内障切除术。
DEX 植入物单独或联合常规辅助 NIU 治疗，在中国患者 NIU 的治疗中是安全有效的。
